Denton, Texas, is poised to become a significant hub for innovative cancer treatment as Novartis announced plans to construct a new $280 million radioligand therapy (RLT) manufacturing facility. The 46,000-square-foot site, announced February 25, 2026, represents a substantial investment in the U.S. Healthcare landscape and is part of the pharmaceutical giant’s broader $23 billion commitment to expanding its operations within the country. This facility will be Novartis’ fifth RLT manufacturing site in the U.S. And its first in the state of Texas, addressing a growing demand for these targeted therapies.
Radioligand therapy is a precision medicine approach that uses radioactive molecules to target and destroy cancer cells. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, RLT aims to deliver treatment directly to the tumor, minimizing damage to surrounding tissues. This targeted approach holds immense promise for improving outcomes for patients with a variety of cancers, and Novartis is actively working to expand its RLT portfolio to encompass earlier treatment lines and a wider range of tumor types. The company emphasizes that the proximity of manufacturing facilities to patients and treatment centers is crucial, as each dose is custom-made and requires timely delivery, with over 99% of doses currently being delivered on schedule.
Expanding Novartis’ U.S. Footprint and RLT Capacity
The new Denton facility is the latest in a series of strategic investments by Novartis in U.S. Manufacturing and research and development. Over the past ten months, the company has broken ground on four new manufacturing and R&D facilities, initiated expansions of three existing sites, and announced two additional locations, demonstrating a clear commitment to bolstering its presence in the American market. The Denton site is expected to create between 150 and 175 jobs in specialized fields such as bioengineering, advanced manufacturing, quality control, and operations, contributing to economic growth in the region. Construction is slated to begin this year, with full operational capacity anticipated by 2028, according to a press release from the company. Novartis highlighted the importance of Texas as a leading biotech hub and a center for medical innovation.
Governor Greg Abbott lauded the investment, stating that it would bring “good-paying jobs in bioengineering, advanced manufacturing and more” to the state. The Denton Record-Chronicle reported that the project will also address environmental issues related to the site’s previous use, returning a dormant property to the tax rolls.
Addressing Environmental Concerns at the Shady Oaks Drive Location
The chosen location for the new facility, in the 2100 block of Shady Oaks Drive in Denton, requires environmental remediation due to past industrial activity. The site was previously occupied by U.S. Radiopharmaceuticals, which ceased operations in 2018, leaving behind radioactive waste. According to the Denton Record-Chronicle, state health officials are involved in overseeing the cleanup process. City Manager Sara Hensley stated that the project will address these environmental issues and revitalize the property. The cleanup timeline has not yet been finalized, but It’s a prerequisite for construction to begin. Prior to U.S. Radiopharmaceuticals, the site was home to Trace Life Sciences, which also manufactured medical radioisotopes.
The Growing Field of Radioligand Therapy
The expansion of RLT manufacturing capacity is driven by the increasing potential of this therapeutic approach in oncology. RLT offers a targeted way to deliver radiation directly to cancer cells, minimizing damage to healthy tissue. This is particularly important for cancers that have spread or are difficult to treat with conventional methods. Novartis CEO Vas Narasimhan emphasized that RLT “has the potential to revolutionize cancer care,” and the company is committed to meeting the growing demand for these next-generation treatments. Community Impact reported that the Denton facility will specifically focus on producing radioligand therapy drugs.
The development of RLT is part of a broader trend toward personalized medicine, where treatments are tailored to the individual characteristics of each patient and their cancer. This approach requires sophisticated manufacturing processes and a robust supply chain to ensure that patients receive the right dose of radiation at the right time. Novartis’ investment in expanding its RLT manufacturing network is a key step in making this type of treatment more accessible to patients in the Southern United States and beyond.
Impact on the Local Economy and Workforce Development
The establishment of the Novartis facility in Denton is expected to have a significant positive impact on the local economy. The creation of 150 to 175 jobs will provide employment opportunities for skilled workers in the region. The project is expected to foster collaboration between Novartis and local educational institutions, potentially offering research partnerships and employment opportunities for college students. The facility will require a workforce with expertise in bioengineering, advanced manufacturing, quality assurance, and operational management. This demand could stimulate educational programs and workforce development initiatives in the Denton area.
The investment also represents a revitalization of a previously underutilized industrial property. The cleanup of the site and the construction of a state-of-the-art manufacturing facility will transform a dormant area into a thriving economic center. This transformation is expected to generate additional tax revenue for the city of Denton and contribute to the overall economic well-being of the community.
Novartis’ Broader Investment in U.S. Manufacturing
The Denton facility is just one component of Novartis’ larger $23 billion investment in U.S. Operations. This investment reflects the company’s confidence in the U.S. Market and its commitment to bringing innovative medicines to patients in the country. In addition to the Denton site, Novartis is also building or expanding manufacturing facilities in New Jersey, Indiana, California, and Florida. This widespread investment demonstrates a strategic effort to strengthen the company’s manufacturing capabilities and ensure a reliable supply of its products to meet growing demand.
The company’s commitment to U.S. Manufacturing is also driven by a desire to reduce reliance on global supply chains and enhance supply chain resilience. By establishing a strong manufacturing presence in the U.S., Novartis aims to mitigate potential disruptions caused by geopolitical events or natural disasters. This strategic approach will help ensure that patients have continued access to the medicines they need, regardless of external factors.
The next key milestone for the project is the commencement of construction this year, with the facility anticipated to be fully operational in 2028. Stakeholders will be closely monitoring the progress of the environmental cleanup and the construction process. Further updates on the project will likely be provided by Novartis and the city of Denton in the coming months. Readers interested in learning more about Novartis’ RLT pipeline and its U.S. Investments can visit the company’s website at www.novartis.com.
What are your thoughts on the expansion of radioligand therapy and its potential impact on cancer treatment? Share your comments below, and please share this article with your network.